What is Fueling Arine’s Growth? We’re Solving a Massive, Urgent Healthcare Challenge

What is Fueling Arine’s Growth? We’re Solving a Massive, Urgent Healthcare Challenge

Arine has, for the second consecutive year, earned a spot on the Inc. 5000 list of fastest-growing private companies—a recognition we’re incredibly proud of. But this accolade represents more than a growth number. Our continued momentum reflects a mission that has guided us from the start: to solve one of the most overlooked and costly challenges in healthcare—medication mismanagement.

A Vast and Urgent Market Opportunity

Medication mismanagement isn’t a fringe issue—it’s a systemic crisis. Research from UC San Diego estimates that non-optimized medication therapy costs the U.S. healthcare system $528.4 billion annually—equivalent to roughly 16% of total U.S. healthcare spending—and claims approximately 275,000 lives each year. This is the challenge Arine was built to solve.

And the timing has never been more urgent. Payers face mounting pressure with medical loss ratios soaring by nearly 3 percentage points in Q4 2024, severely pressing margins and profitability. The shift toward value-based care is also accelerating, with healthcare systems tackling areas prone to overuse or waste.

As our Senior Vice President of Client Growth & Strategy, Amy Mosher-Garvey, notes:

“Even just 18–24 months ago, few health plans saw medications as a way to both improve care and reduce costs. Today, with mounting pressures and proven outcomes from medication optimization, it has become a central strategy—and Arine is helping plans move on it with urgency to deliver results.”

Outcomes and Client Validation

The true measure of our growth lies in the results we deliver for the patients and partners we serve:

• Over 40% reduction in hospitalizations — preventing thousands of avoidable admissions and reducing strain on healthcare systems.
• More than 20% reduction in emergency department visits — keeping patients healthier and lowering avoidable acute care costs.
• Greater than 10% reduction in total cost of care — delivering measurable financial savings alongside clinical improvements.

These aren’t pilot results—they’re outcomes achieved across diverse, large-scale populations, helping our health plan partners excel in value-based care and improve quality performance metrics.

These results underscore both the immediate financial benefits—and, importantly, the scalable, sustainable health outcomes we’re achieving with our partners. Over the past three years, Arine has grown 1,000% in revenue, and in the past year alone, existing clients have expanded their partnerships with us by an average of 80%. This growth reflects both the trust we’ve earned and the increasing recognition that our medication optimization solutions deliver lasting value.

Looking Ahead: Recognition That Validates Our Mission

Being named to the Inc. 5000 list two years running is an honor that represents more than business validation. It signifies that our mission resonates. Every percentage point of reduced hospitalization, every dollar saved, every life impacted—these are the outcomes that drive our success.

This recognition confirms that Arine’s mission and business performance are intertwined. And with the support of our recent Series C funding, we’re accelerating innovation, expanding our reach, and scaling the technology and clinical expertise needed to solve medication mismanagement at the population level. As the urgency for medication optimization continues to grow, we’re committed to staying at the forefront—innovating, partnering deeply, and scaling our impact across the healthcare system.

Here’s to continued growth—powered by purpose.